Pulmatrix PE Ratio 2014-2021 | PULM

Current and historical p/e ratio for Pulmatrix (PULM) from 2014 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Pulmatrix PE ratio as of October 26, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Pulmatrix PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-27 0.78 0.00
2021-06-30 1.04 $-0.52 0.00
2021-03-31 1.33 $-0.50 0.00
2020-12-31 1.19 $-0.64 0.00
2020-09-30 1.19 $-0.76 0.00
2020-06-30 1.72 $-0.63 0.00
2020-03-31 1.01 $-0.99 0.00
2019-12-31 0.86 $-1.50 0.00
2019-09-30 0.82 $-1.33 0.00
2019-06-30 0.92 $-2.15 0.00
2019-03-31 1.27 $-3.04 0.00
2018-12-31 2.40 $-4.70 0.00
2018-09-30 3.70 $-4.70 0.00
2018-06-30 4.50 $-5.90 0.00
2018-03-31 5.09 $-7.50 0.00
2017-12-31 14.10 $-7.20 0.00
2017-09-30 20.50 $-7.20 0.00
2017-06-30 23.80 $-7.10 0.00
2017-03-31 34.90 $-10.40 0.00
2016-12-31 5.90 $-12.10 0.00
2016-09-30 16.50 $-16.70 0.00
2016-06-30 19.60 $-18.00 0.00
2016-03-31 29.30 $-38.40 0.00
2015-12-31 42.00 $-34.60 0.00
2015-09-30 49.10 $-47.25 0.00
2015-06-30 96.00 $-52.60 0.00
2015-03-31 86.00 $-35.00 0.00
2014-12-31 87.50 $-46.50 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.040B $0.013B
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86